AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MIAMI BEACH -- Serum levels of soluble endoglin and soluble fms-like tyrosine kinase 1 are increased months before onset of clinical disease in patients with preeclampsia, Dr. Richard Levine said at the annual meeting of the Society for Maternal-Fetal Medicine.
The findings suggest that a circulating antiangiogenic state is important in the pathogenesis of this maternal syndrome, said Dr. Levine of the National Institute of Child Health and Human Development, Bethesda, Md.
"We believe that soluble endoglin [a cell surface receptor for the proangiogenic protein transforming growth factor-[beta] and soluble fms-like tyrosine kinase 1 [an antiangiogenic factor that binds placental growth factor and vascular endothelial growth factor] act in concert to produce the maternal syndrome or preeclampsia," he said.
A nested case-control study of the Calcium for Preeclampsia Prevention (CPEP) trial cohort of healthy nulliparas showed that compared with serum samples from gestational age-matched controls, the levels of these factors were significantly higher beginning 9-11 weeks before preterm preeclampsia. After preeclampsia onset, soluble endoglin (sEng) levels were almost fivefold higher (46 vs. 10 ng/mL) and soluble fms-like tyrosine kinase 1 (sFlt1) levels were nearly threefold higher (6,356 vs. 2,316 pg/mL). Placental growth ...